Neuroimaging Studies of Cannabidiol and Potential Neurobiological Mechanisms Relevant for Alcohol Use Disorders: a Systematic Review

Overview

Journal J Cannabis Res

Date 2024 Mar 21

PMID 38509580

Authors

Tristan Hurzeler

Joshua Watt

Warren Logge

Ellen Towers

Anastasia Suraev

Nicholas Lintzeris

Paul Haber

Kirsten C Morley

Affiliations

Soon will be listed here.

Abstract

The underlying neurobiological mechanisms of cannabidiol's (CBD) management of alcohol use disorder (AUD) remains elusive.Aim We conducted a systematic review of neuroimaging literature investigating the effects of CBD on the brain in healthy participants. We then theorise the potential neurobiological mechanisms by which CBD may ameliorate various symptoms of AUD.Methods This review was conducted according to the PRISMA guidelines. Terms relating to CBD and neuroimaging were used to search original clinical research published in peer-reviewed journals.Results Of 767 studies identified by our search strategy, 16 studies satisfied our eligibility criteria. The results suggest that CBD modulates γ-Aminobutyric acid and glutamate signaling in the basal ganglia and dorso-medial prefrontal cortex. Furthermore, CBD regulates activity in regions associated with mesocorticolimbic reward pathways; salience, limbic and fronto-striatal networks which are implicated in reward anticipation; emotion regulation; salience processing; and executive functioning.Conclusion CBD appears to modulate neurotransmitter systems and functional connections in brain regions implicated in AUD, suggesting CBD may be used to manage AUD symptomatology.

Citing Articles

The neurobehavioural effects of cannabidiol in alcohol use disorder: Study protocol for a double-blind, randomised, cross over, placebo-controlled trial.

Hurzeler T, Logge W, Watt J, DeMayo M, Suraev A, McGregor I Contemp Clin Trials Commun. 2024; 41:101341.

PMID: 39252861 PMC: 11382041. DOI: 10.1016/j.conctc.2024.101341.

References

Viudez-Martinez A, Garcia-Gutierrez M, Fraguas-Sanchez A, Torres-Suarez A, Manzanares J . Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Br J Pharmacol. 2018; 175(16):3369-3378. PMC: 6057893. DOI: 10.1111/bph.14380. View

Lapish C, Seamans J, Chandler L . Glutamate-dopamine cotransmission and reward processing in addiction. Alcohol Clin Exp Res. 2006; 30(9):1451-65. DOI: 10.1111/j.1530-0277.2006.00176.x. View

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J . Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016; 15(3):270-8. DOI: 10.1016/S1474-4422(15)00379-8. View

Crippa J, Guimaraes F, Campos A, Zuardi A . Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol. 2018; 9:2009. PMC: 6161644. DOI: 10.3389/fimmu.2018.02009. View

Arout C, Haney M, Herrmann E, Bedi G, Cooper Z . A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br J Clin Pharmacol. 2021; 88(1):347-355. DOI: 10.1111/bcp.14973. View

Skelley J, Deas C, Curren Z, Ennis J . Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). 2019; 60(1):253-261. DOI: 10.1016/j.japh.2019.11.008. View

Ren Y, Whittard J, Higuera-Matas A, Morris C, Hurd Y . Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009; 29(47):14764-9. PMC: 2829756. DOI: 10.1523/JNEUROSCI.4291-09.2009. View

Linden D, Prvulovic D, Formisano E, Vollinger M, Zanella F, Goebel R . The functional neuroanatomy of target detection: an fMRI study of visual and auditory oddball tasks. Cereb Cortex. 1999; 9(8):815-23. DOI: 10.1093/cercor/9.8.815. View

Morley K . Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact. Addiction. 2021; 116(11):3027-3028. DOI: 10.1111/add.15532. View

10.

Lawn W, Hill J, Hindocha C, Yim J, Yamamori Y, Jones G . The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. J Psychopharmacol. 2020; 34(9):969-980. PMC: 7745615. DOI: 10.1177/0269881120944148. View

11.

Brown S, Martinez M, Parsons L . Passive music listening spontaneously engages limbic and paralimbic systems. Neuroreport. 2004; 15(13):2033-7. DOI: 10.1097/00001756-200409150-00008. View

12.

Bhattacharyya S, Crippa J, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P . Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry. 2012; 69(1):27-36. DOI: 10.1001/archgenpsychiatry.2011.161. View

13.

Hargreaves R, Hoppin J, Sevigny J, Patel S, Chiao P, Klimas M . Optimizing Central Nervous System Drug Development Using Molecular Imaging. Clin Pharmacol Ther. 2015; 98(1):47-60. DOI: 10.1002/cpt.132. View

14.

Heeger D, Ress D . What does fMRI tell us about neuronal activity?. Nat Rev Neurosci. 2002; 3(2):142-51. DOI: 10.1038/nrn730. View

15.

Pretzsch C, Voinescu B, Mendez M, Wichers R, Ajram L, Ivin G . The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol. 2019; 33(9):1141-1148. PMC: 6732821. DOI: 10.1177/0269881119858306. View

16.

Bergamaschi M, Queiroz R, Chagas M, de Oliveira D, De Martinis B, Kapczinski F . Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011; 36(6):1219-26. PMC: 3079847. DOI: 10.1038/npp.2011.6. View

17.

Oscar-Berman M, Marinkovic K . Alcohol: effects on neurobehavioral functions and the brain. Neuropsychol Rev. 2007; 17(3):239-57. PMC: 4040959. DOI: 10.1007/s11065-007-9038-6. View

18.

George O, Sanders C, Freiling J, Grigoryan E, Vu S, Allen C . Recruitment of medial prefrontal cortex neurons during alcohol withdrawal predicts cognitive impairment and excessive alcohol drinking. Proc Natl Acad Sci U S A. 2012; 109(44):18156-61. PMC: 3497825. DOI: 10.1073/pnas.1116523109. View

19.

Haney M, Malcolm R, Babalonis S, Nuzzo P, Cooper Z, Bedi G . Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology. 2015; 41(8):1974-82. PMC: 4908634. DOI: 10.1038/npp.2015.367. View

20.

Rubia K, Smith A, Brammer M, Taylor E . Temporal lobe dysfunction in medication-naïve boys with attention-deficit/hyperactivity disorder during attention allocation and its relation to response variability. Biol Psychiatry. 2007; 62(9):999-1006. DOI: 10.1016/j.biopsych.2007.02.024. View